Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large,
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (…

Background In the RV144 trial, the estimated efficacy of a vaccine regimen against human
immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case–control analysis to …

Background Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to
protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid …

The recent epidemiologic and clinical literature is filled with studies evaluating statistical
models for predicting disease or some other adverse event. Risk stratification tables are a new …

The case–crossover design has been widely used to study the association between short-term
air pollution exposure and the risk of an acute adverse health event. The design uses …

Background At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 …

Research methods for biomarker evaluation lag behind those for evaluating therapeutic
treatments. Although a phased approach to development of biomarkers exists and guidelines …

A marker strongly associated with outcome (or disease) is often assumed to be effective for
classifying persons according to their current or future outcome. However, for this assumption …

Background In the Step Study, the MRKAd5 HIV-1 gag/pol/nef vaccine did not reduce plasma
viraemia after infection, and HIV-1 incidence was higher in vaccine-treated than in placebo-…

The restricted neutralization breadth of vaccine-elicited antibodies is a major limitation of
current human immunodeficiency virus-1 (HIV-1) candidate vaccines. In order to permit the …